BUZZ - As Eli Lilly expands access to weight loss drugs through its platform, "Hims & Hers" emerges

Latest Developments

November 6 - ** The stock price of telemedicine platform Hims & Hers Health (HIMS.N) rose 6% in early trading to $25.65

** Reportedly, under a new agreement, Eli Lilly (LLY.N)'s weight loss drugs Zepbound and Foundayo will be available through the Hims & Hers platform

** Eligible patients prescribed by providers on the platform can access Eli Lilly's self-pay prices without having to leave the Hims & Hers platform

** Eli Lilly’s weight loss injection Zepbound starts at $299 per month, and oral weight loss medication Foundayo starts at $149 per month

** Hims & Hers stated that patients can complete consultations on the platform, receive prescriptions when appropriate, and have FDA-approved Eli Lilly medications shipped directly to their homes

** Hims stated the company has never offered compounded generic versions of Eli Lilly's GLP-1 weight loss drugs and promises not to do so in the future

** Including this transaction, the stock has dropped approximately 21% so far this year

(To facilitate non-English speakers, Reuters provides automated translations of its reports into several other languages. Because automated translation may contain errors or lack intended context, Reuters does not guarantee the accuracy of the automated translations and provides them solely for readers’ convenience. Reuters is not liable for any damages or losses resulting from the use of automated translation features.)